Zomedica Pharmaceuticals Corp Stock In The News
| ZOM Stock | USD 0.12 0 2.50% |
Our overall analysis of Zomedica Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Zomedica Pharmaceuticals Corp. The specific impact of Zomedica Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Zomedica Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Zomedica Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Zomedica Pharmaceuticals Backtesting and Zomedica Pharmaceuticals Hype Analysis.
Zomedica |
Zomedica Pharmaceuticals Today Top News and Investor Outlook
Zomedica Pharmaceuticals Corp Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Zomedica and other traded companies coverage with news coverage. We help investors stay connected with Zomedica headlines for the 13th of December 2024 to make an informed investment decision based on correlating the impacts of news items on Zomedica Stock performance. Please note that trading solely based on the Zomedica Pharmaceuticals Corp hype is not for everyone as timely availability and quick action are needed to avoid losses.
Zomedica Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Zomedica earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Zomedica Pharmaceuticals that are available to investors today. That information is available publicly through Zomedica media outlets and privately through word of mouth or via Zomedica internal channels. However, regardless of the origin, that massive amount of Zomedica data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Zomedica Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Zomedica Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Zomedica Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Zomedica Pharmaceuticals alpha.
Zomedica Largest EPS Surprises
Earnings surprises can significantly impact Zomedica Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-08-10 | 2020-06-30 | -0.01 | -0.02 | -0.01 | 100 | ||
2020-02-26 | 2019-12-31 | -0.02 | -0.03 | -0.01 | 50 | ||
2019-11-12 | 2019-09-30 | -0.02 | -0.03 | -0.01 | 50 | ||
2019-08-08 | 2019-06-30 | -0.06 | -0.02 | 0.04 | 66 |
Zomedica Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Zomedica Pharmaceuticals Stock. Current markets are slightly bullish. About 55% of major world exchanges and indexes are currently up. See today's market update for more information.
5th of December 2024
LightPath Technologies Introduces New Optical Gas Imaging Camera for Ammonia and SF6 Detec... at finance.yahoo.com
5th of December 2024
Are You Missing Out On This NASDAQ-Listed Weed Stock Low-Cost Model Meets European Demand at benzinga.com
4th of December 2024
Down 40 percent This Year, Is Tilray Brands Stock Due for a Much Better Performance in 202... at finance.yahoo.com
4th of December 2024
Aurora Cannabis Trading Down 4.6 percent - Should You Sell - MarketBeat at news.google.com
27th of November 2024
Flora Growth Taps Europes CBD Boom With 500K Czech-Slovak Partnership Renewal at benzinga.com
26th of November 2024
Lifecore Biomedical, Inc. Soars 36 percent But Its A Story Of Risk Vs Reward at simplywall.st
21st of November 2024
Redhook Brewery and Montlake Futures Team Up to Launch Montlake Gameday Gold Lager, a New ... at globenewswire.com
21st of November 2024
Lifecore Biomedical Hosts Virtual Investor Day at gurufocus.com
20th of November 2024
Aurora Cannabis Expands Innovative Recreational Product Portfolio at finance.yahoo.com
20th of November 2024
Canopy Growth Launches Claybourne Infused Pre-Rolls in Canada at finance.yahoo.com
19th of November 2024
Short Interest in Aquestive Therapeutics, Inc. Declines By 6.0 at thelincolnianonline.com
15th of November 2024
ARMISTICE CAPITAL, LLC Acquires New Stake in Aquestive Therapeutics Inc at gurufocus.com
15th of November 2024
Cronos Group Third Quarter 2024 Earnings Beats Expectations - Simply Wall St at news.google.com
13th of November 2024
Acquisition by Robert Cohen of 1823107 shares of Zomedica Pharmaceuticals at 0.13 subject ... at MacroaxisInsider
13th of November 2024
Shuttle Pharma Provides Third Quarter 2024 Corporate Update at globenewswire.com
13th of November 2024
Cronos Group Inc. Q3 2024 Earnings Call Transcript at insidermonkey.com
11th of November 2024
Acquisition by Russell Klass of 210200 shares of Zomedica Pharmaceuticals at 0.12 subject ... at Russell Klass
8th of November 2024
Acquisition by Anthony Blair of 150000 shares of Zomedica Pharmaceuticals at 0.123 subject... at finance.yahoo.com
7th of November 2024
Aurora Cannabis Q2 2025 Earnings Call Transcript at fool.com
7th of November 2024
SNDL Inc. Just Released Its Third-Quarter Earnings Heres What Analysts Think at finance.yahoo.com
6th of November 2024
Aquestive Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Growth Amidst ... at finance.yahoo.com
4th of November 2024
Aquestive Therapeutics GAAP EPS of -0.13 in-line, revenue of 13.54M beats by 0.86M at seekingalpha.com
31st of October 2024
Cannabis Stock Gainers And Losers From October 31, 2024 at benzinga.com
30th of October 2024
Shuttle Pharmaceuticals dips 6, prices 3.5M share offering at seekingalpha.com
28th of October 2024
Disposition of 31361 shares by Gorenstein Michael Ryan of Cronos subject to Rule 16b-3 at MacroaxisInsider
25th of October 2024
Shuttle Pharmaceuticals completes funding round, raises 790,000 - Investing.com at news.google.com
24th of October 2024
ZOM - Zomedica Corp. Latest Stock News Market Updates - StockTitan at news.google.com
24th of October 2024
Tilray Trading Down 0.2 percent Should You Sell at thelincolnianonline.com
23rd of October 2024
Marijuana Stock Movers For October 23, 2024 at benzinga.com
17th of October 2024
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer at finance.yahoo.com
14th of October 2024
Acquisition by Ann Cotter of 8333 shares of Zomedica Pharmaceuticals at 0.11 subject to Ru... at Ann Cotter
9th of October 2024
Zomedica Corp Q2 2024 Earnings Call Highlights Diagnostics Surge Amid Revenue Challenges at gurufocus.com
7th of October 2024
Lifecore Biomedical, Inc. Q1 2025 Earnings Call Transcript at insidermonkey.com
9th of August 2024
Should You Invest on Alimera Sciences, Inc. Right Now at finance.yahoo.com
5th of August 2024
AnaptysBio, Inc. Reports Q2 Loss, Misses Revenue Estimates at zacks.com
1st of July 2024
Lucy Scientific shares to be delisted from Nasdaq By Investing.com - Investing.com India at news.google.com
24th of June 2024
ALIM Stock Alert Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, I... at businesswire.com
19th of July 2023
SHAREHOLDER ALERT Pomerantz Law Firm Reminds Shareholders with Losses on their Investment ... at benzinga.com
6th of July 2023
Mallinckrodt open to proposed transactions as it struggles to pay opioid settlement stock ... at marketwatch.com
5th of July 2023
Tasso, United BioSource partner to improve sample collection - FierceBiotech at news.google.com
22nd of June 2023
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Preve... at globenewswire.com
14th of June 2023
HEXO Reports Q3 Loss, Lags Revenue Estimates at finance.yahoo.com
30th of May 2023
Acquisition by Versi Ebrahim of 8745 shares of Adamis Pharma subject to Rule 16b-3 at MacroaxisInsider
25th of May 2023
Gland Pharma Analyzing customer concentration risk - Indiainfoline at news.google.com
15th of May 2023
Hero or Zero 3 Speculative Cannabis Stocks to Make You Rich or ... - InvestorPlace at news.google.com
15th of May 2023
Adamis Q1 Earnings Snapshot at finance.yahoo.com
15th of May 2023
Athenex Shares Tumble Premarket After Chapter 11 Filing ATNX at marketwatch.com
1st of May 2023
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination w... at finance.yahoo.com
11th of April 2023
Tilray, Hexo stocks fall sharply after MA deal at marketwatch.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zomedica Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zomedica Pharmaceuticals' short interest history, or implied volatility extrapolated from Zomedica Pharmaceuticals options trading.
Check out Zomedica Pharmaceuticals Backtesting and Zomedica Pharmaceuticals Hype Analysis. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.